肿瘤细胞治疗研究
ALL SOURCES
Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 ag
我们的临床前数据表明，利用靶向肿瘤的 TGFβ1 印记 IL1RAP-CAR-NK 细胞，联合 IL-15 激动剂和抗 GD2 抗体所进行的组合性先天免疫治疗，是一种有前景的针对转移性/复发性/难治性 ES 的新型治疗策略。
A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.
GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches.
GD2 在小儿骨肉瘤中是一个具有生物学相关性和临床前景的靶点。然而，重大的转化挑战仍然存在，包括有限的临床数据、异质性的研究设计，以及缺乏用于 GD2 表达评估的标准化检测方法。需要进一步的国际合作研究，以优化患者选择并加速 GD2 靶向联合免疫治疗策略的开发。
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
CAR-T cell therapy and reconstructive oncologic surgery in peripheral solid tumors-A narrative review.
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
这是一项 I 期注册临床试验，评估 GD2NK 细胞治疗神经母细胞瘤、骨肉瘤的疗效与安全性。当前状态：招募中。计划入组 27 例。试验地点：美国 · 休斯顿（共 1 个中心）。登记号：NCT07211737。
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights.
Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid
这是第三代 GD2 靶向 CAR-T 细胞在转移性黑色素瘤及其他实体癌（如结直肠癌）患者中的首次报告，显示了可行性、安全性和免疫活性，但临床效果有限。
MEMBER ACCOUNT
登录成功会直接打开下一页。
